Vivatides Therapeutics closed an oversubscribed $54 million Series A to advance extrahepatic RNA therapeutics, focusing on improvements to delivery technologies and preclinical optimization. The company said proceeds will support further development of its extrahepatic delivery platform, accelerate IND-enabling studies, and move pipeline programs toward clinical development. Extrahepatic delivery is a key constraint for RNA therapeutics, because many systems concentrate in the liver. Vivatides’ financing adds to a growing set of delivery-focused investments as RNA platform developers compete on targeting specificity, tissue distribution, and manufacturability for potential first-in-human programs.